The Taskforce notes that on Friday, February 24, 2022, the Therapeutic Goods Administration (TGA) granted provisional approval for tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis (prevention).
Taskforce guidance on the use of Evusheld will be published early next week.
Ends.